Joel Isaacson & Co’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Joel Isaacson & Co’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$240K	Hold	3,025	–	–	0.01%	403
2025 Q4	$249K	Hold	3,025	–	–	0.01%	397
2025 Q3	$211K	Buy	+3,025	New	+$204K	0.01%	420
2025 Q2	–	Sell	-6,730	Closed	-$427K	–	430
2025 Q1	$427K	Hold	6,730	–	–	0.02%	258
2024 Q4	$448K	Hold	6,730	–	–	0.02%	245
2024 Q3	$470K	Hold	6,730	–	–	0.02%	232
2024 Q2	$436K	Hold	6,730	–	–	0.02%	237
2024 Q1	$436K	Hold	6,730	–	–	0.02%	229
2023 Q4	$443K	Hold	6,730	–	–	0.03%	205
2023 Q3	$384K	Hold	6,730	–	–	0.03%	218
2023 Q2	$412K	Hold	6,730	–	–	0.03%	211
2023 Q1	$422K	Hold	6,730	–	–	0.03%	204
2022 Q4	$427K	Hold	6,730	–	–	0.03%	203
2022 Q3	$397K	Hold	6,730	–	–	0.03%	190
2022 Q2	$389K	Hold	6,730	–	–	0.03%	191
2022 Q1	$408K	Hold	6,730	–	–	0.03%	207
2021 Q4	$479K	Hold	6,730	–	–	0.03%	191
2021 Q3	$504K	Hold	6,730	–	–	0.04%	180
2021 Q2	$520K	Hold	6,730	–	–	0.04%	173
2021 Q1	$497K	Hold	6,730	–	–	0.04%	156
2020 Q4	$472K	Hold	6,730	–	–	0.05%	153
2020 Q3	$381K	Hold	6,730	–	–	0.05%	151
2020 Q2	$392K	Hold	6,730	–	–	0.06%	138
2020 Q1	$313K	Hold	6,730	–	–	0.05%	135
2019 Q4	$376K	Hold	6,730	–	–	0.05%	152
2019 Q3	$319K	Hold	6,730	–	–	0.05%	159
2019 Q2	$360K	Hold	6,730	–	–	0.05%	148
2019 Q1	$371K	Hold	6,730	–	–	0.05%	153
2018 Q4	$350K	Hold	6,730	–	–	0.06%	161
2018 Q3	$400K	Hold	6,730	–	–	0.06%	144
2018 Q2	$368K	Hold	6,730	–	–	0.06%	146
2018 Q1	$331K	Hold	6,730	–	–	0.06%	146
2017 Q4	$317K	Hold	6,730	–	–	0.06%	147
2017 Q3	$336K	Hold	6,730	–	–	0.06%	140
2017 Q2	$307K	Hold	6,730	–	–	0.06%	142
2017 Q1	$285K	Sell	6,730 -160	-2%	-$6.71K	0.06%	140
2016 Q4	$267K	Hold	6,890	–	–	0.05%	134
2016 Q3	$289K	Hold	6,890	–	–	0.06%	138
2016 Q2	$255K	Hold	6,890	–	–	0.05%	145
2016 Q1	$264K	Hold	6,890	–	–	0.06%	146
2015 Q4	$348K	Hold	6,890	–	–	0.09%	110
2015 Q3	$315K	Hold	6,890	–	–	0.08%	110
2015 Q2	$402K	Hold	6,890	–	–	0.1%	99
2015 Q1	$380K	Hold	6,890	–	–	0.1%	104
2014 Q4	$346K	Hold	6,890	–	–	0.09%	103
2014 Q3	$318K	Hold	6,890	–	–	0.1%	86
2014 Q2	$301K	Hold	6,890	–	–	0.09%	94
2014 Q1	$287K	Buy	+6,890	New	+$295K	0.1%	94

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Joel Isaacson & Co's PBE Position: Q1 2026 in Review

Joel Isaacson & Co held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 3,025 shares worth $240K. The position accounts for 0.01% of the portfolio, ranked #403.

Joel Isaacson & Co first reported a position in PBE in Q1 2014 and has held it in 48 quarters since. The position peaked at $520K in Q2 2021. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

Joel Isaacson & Co held 3,025 shares of Invesco Biotechnology & Genome ETF worth $240K as of Q1 2026.
Joel Isaacson & Co left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
Invesco Biotechnology & Genome ETF made up 0.01% of Joel Isaacson & Co's portfolio in Q1 2026, its #403 holding.
Joel Isaacson & Co first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and has held it in 48 quarters since.
Joel Isaacson & Co's Invesco Biotechnology & Genome ETF position peaked at $520K in Q2 2021.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Joel Isaacson & Co's 13F filing for Q1 2026, filed 23 Apr 2026.